Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 6/20 | 0.49 |
| ▸ | HTR2C | P28335 | 6/20 | 0.49 |
| ▸ | HTR2B | P41595 | 6/20 | 0.49 |
| ▸ | TDP2 | O95551 | 2/20 | 0.47 |
| ▸ | PNMT | P11086 | 4/20 | 0.40 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | CDC7 | O00311 | 1/20 | 0.38 |
| ▸ | XIAP | P98170 | 1/20 | 0.37 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14401750 | 0.77 | AR (0.44) | PARP1PARP10HTR2AHTR2CHTR2B | |
| SCHEMBL12156816 | 0.77 | AR (0.44) | PARP1PARP10HTR2AHTR2CHTR2B | |
| SCHEMBL21132327 | 0.76 | ACHE (0.63) | PARP1PARP10HTR2AHTR2CHTR2B | |
| SCHEMBL21470711 | 0.76 | TSHR (0.60) | TSHRTDP2MKNK1CDC7 | |
| SCHEMBL30285537 | 0.76 | TSHR (0.60) | TSHRPARP1PARP10HTR2AHTR2C | |
| SCHEMBL21333673 | 0.76 | TSHR (0.60) | TSHRPARP1PARP10HTR2AHTR2C | |
| SCHEMBL31739118 | 0.73 | PARP1 (0.43) | PARP1PARP10HTR2AHTR2CHTR2B | |
| SCHEMBL30681290 | 0.72 | PARP10 (0.71) | PARP1PARP10HTR2AHTR2CHTR2B | |
| SCHEMBL12203700 | 0.72 | TSHR (1.00) | TSHRPARP1PARP10HTR2AHTR2C | |
| SCHEMBL6448571 | 0.72 | TSHR (1.00) | TSHRPARP1PARP10HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| CN-103108871-B | 17a-hydroxylase/c17,20-lyase inhibitors | NOVARTIS AG | 2014-09-10 | — | — | CN | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| EP-2627648-A1 | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS | Novartis AG (CH) | 2013-08-21 | — | — | EP | disclosed |
| WO-2012035078-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012035078-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | TSHR 3077/4885PARP1 2549/4885PARP10 940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.